Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359177 · ClinicalTrials.gov registry record · Phase 1
Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment
A Phase 1 study of Vomiting, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT00359177: Completed Phase 1 study of Vomiting, sponsored by GlaxoSmithKline.
NCT00359177 is a Phase 1 study of Vomiting that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants, below the 104-participant average among 9 other Vomiting trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00359177, a Phase 1 study of Vomiting, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to evaluate how subjects with mild or moderate liver problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.
Primary Outcome
Blood samples for pharmacokinetics (PK) analysis will be collected at the indicated time points. AUC will be calculated from plasma GW679769 concentration.
Conditions Studied
Interventions
- DRUG GW679769
Study Locations (2)
Florida
- GSK Investigational Site - Gainesville
- GSK Investigational Site - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-12-01 |
| Est. Completion | 2006-10-12 |
| Phase | Phase 1 |
What the finished NCT00359177 record still lists
NCT00359177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 104-participant average among 9 other Vomiting trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Vomiting appearing as the primary indexed condition, and to 1 intervention - of which GW679769 is the first listed.
NCT00359177 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00359177 about?
NCT00359177 is a clinical study titled "Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment". The purpose of the study is to evaluate how subjects with mild or moderate liver problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.
What is the current status of trial NCT00359177?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2005-12-01. Estimated completion is 2006-10-12.
What conditions does trial NCT00359177 study?
This clinical trial studies the following conditions: Vomiting.
What interventions are being tested in trial NCT00359177?
The interventions under investigation include: GW679769 (DRUG).
Who is sponsoring clinical trial NCT00359177?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00359177 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vomiting
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00359177's enrollment target sits among peer trials
24 10th of 9 the lowest of 9 other Vomiting trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vomiting trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GI Alpha-Gal Study
RECRUITING · NA
-
Inhaled Isopropyl Alcohol for Treatment of Nausea
RECRUITING · Phase 2
-
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
RECRUITING · NA
-
Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI